Search

BACKGROUND: Deep brain stimulation (DBS) has been increasingly used in the management of dyskinetic cerebral palsy (DCP). Data on long-term effects and the safety profile are rare. OBJECTIVES: We assessed the efficacy and safety of pallidal DBS in pediatric patients with DCP. METHODS: The STIM-CP trial was a prospective, single-arm, multicenter study in which patients from the parental trial agreed to be followed-up for up to 36 months. Assessments included motor and non-motor domains. RESULTS: Of the 16 patients included initially, 14 (mean inclusion age 14 years) were assessed. There was a significant change in the (blinded) ratings of the total Dyskinesia Impairment Scale at 36 months. Twelve serious adverse events (possibly) related to treatment were documented. CONCLUSION: DBS significantly improved dyskinesia, but other outcome parameters did not change significantly. Investigations of larger homogeneous cohorts are needed to further ascertain the impact of DBS and guide treatment decisions in DCP. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. ispartof: Mov Disord ispartof: location:United States status: Published online

Objective: The NF2 gene is a typical tumor suppressor gene and is biallelically inactivated in vestibular schwannomas, both NF2-associated and sporadic. For tumors with two minor intragenic inactivating NF2 mutations, an interesting issue is which one occurred first. We addressed this question by comparing [for full text, please go to the a.m. URL]

Objective: CAR-T cells have emerged as a promising tool for immunotherapy in oncological patients. Previous studies could show evidence for various solid tumor entities like e.g. glioblastoma. Since nerve sheath tumors like NF2-associated Vestibular Schwannoma (NF2-VS) as well as Malignant Peripheral [for full text, please go to the a.m. URL]

Objective: Impairment of mobility by gait disturbances is a common clinical problem in Parkinson’s disease after bilateral deep brain stimulation of the subthalamic nucleus. We aimed to describe subregions of the subthalamic space where neurostimulation has a positive effect on gait or provokes [for full text, please go to the a.m. URL]

Objective: While deep brain stimulation is a well-established treatment for Parkinson’s Disease, there are still multiple factors of discussion on its best performance, especially fhe value of awake DBS to guide the implantation process. Intraoperative assessment of symptom control and side effect [for full text, please go to the a.m. URL]

Objective: Nucleus Basalis of Meynert (NBM) is a group of cholinergic neurons in the basal forebrain that have a role in various cognitive functions. Animal and postmortem studies reveal widespread projections to the neocortex, hippocampus, and other cortical and subcortical structures. In cases of [for full text, please go to the a.m. URL]

BACKGROUND: Patients with dyskinetic cerebral palsy are often severely impaired with limited treatment options. The effects of deep brain stimulation (DBS) are less pronounced than those in inherited dystonia but can be associated with favorable quality of life outcomes even in patients without changes in dystonia severity. OBJECTIVE: The aim is to assess DBS effects in pediatric patients with pharmacorefractory dyskinetic cerebral palsy with focus on quality of life. METHODS: The method used is a prospective, single-arm, multicenter study. The primary endpoint is improvement in quality of life (CPCHILD [Caregiver Priorities & Child Health Index of Life with Disabilities]) from baseline to 12 months under therapeutic stimulation. The main key secondary outcomes are changes in Burke-Fahn-Marsden Dystonia Rating Scale, Dyskinesia Impairment Scale, Gross Motor Function Measure-66, Canadian Occupational Performance Measure (COPM), and Short-Form (SF)-36. After 12 months, patients were randomly assigned to a blinded crossover to receive active or sham stimulation for 24 hours each. Severity of dystonia and chorea were blindly rated. Safety was assessed throughout. The trial was registered at ClinicalTrials.gov, number NCT02097693. RESULTS: Sixteen patients (age: 13.4 ± 2.9 years) were recruited by seven clinical sites. Primary outcome at 12-month follow-up is as follows: mean CPCHILD increased by 4.2 ± 10.4 points (95% CI [confidence interval] -1.3 to 9.7; P = 0.125); among secondary outcomes: improvement in COPM performance measure of 1.1 ± 1.5 points (95% CI 0.2 to 1.9; P = 0.02) and in the SF-36 physical health component by 5.1 ± 6.2 points (95% CI 0.7 to 9.6; P = 0.028). Otherwise, there are no significant changes. CONCLUSION: Evidence to recommend DBS as routine treatment to improve quality of life in pediatric patients with dyskinetic cerebral palsy is not yet sufficient. Extended follow-up in larger cohorts will determine the impact of DBS further to guide treatment decisions in these often severely disabled patients. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. ispartof: MOVEMENT DISORDERS vol:37 issue:4 pages:799-811 ispartof: location:United States status: published

Objective: PD dementia (PDD) patients are excluded from the highly effective treatment of STN-DBS since dementia is an accepted contraindication. The DEMPARK study is an ongoing phase-1b trial at our institution with an exploratory endpoint on cognition by combined STN and Nucleus basalis of Meynert[for full text, please go to the a.m. URL], 72. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgie

Objective: This study aims to evaluate the relationship of total nimodipine dosage, tumor size, hearing and facial nerve preservation in vestibular schwannoma surgery. Methods: In a retrospective analysis the data of 93 patients out of 112 patients of a randomized, multicenter trial that investigated[for full text, please go to the a.m. URL], 72. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgie

Objective: Deep brain stimulation is a well-established treatment for Parkinson's Disease. Directional deep brain stimulation (dDBS) leads offer the opportunity of steering current in horizontal and vertical directions and expands the therapeutic window in individuals compared to ring mode. Till[for full text, please go to the a.m. URL], 71. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), 9. Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie

Additional file 1: Additional details pertaining to material and methods. Details of cell culture. Figure S1. Unaltered full-length Western-blots of ADAM9, Merlin and γ-Tubulin protein expression in VS and VS primary cells from Fig. 1. Figure S2. Unaltered full-length Western-blots of Merlin, ADAM9 and γ-Tubulin protein expression in VS primary cells. Figure S3. Split-channel presentation of ADAM9 co-localization with Integrin α6 and Integrin α2β1 in VS tumor samples as shown in Fig. 3.